Cisplatin contributes to programmed death-ligand 1 expression in bladder cancer through ERK1/2-AP-1 signaling pathway

Bladder cancer (BC) is the second most common urologic malignancy and the ninth most common malignancy worldwide. Surgical resection is the mainstay of treatment for patients with early-stage disease, whereas therapeutic options are limited for patients with advanced-stage or residual BC. Programmed...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Te-Fu, Lin, Ji-Fan, Lin, Yi-Chia, Chou, Kuang-Yu, Chen, Hung-En, Ho, Chao-Yen, Chen, Po-Chun, Hwang, Thomas I-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783655/
https://www.ncbi.nlm.nih.gov/pubmed/31341011
http://dx.doi.org/10.1042/BSR20190362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783655/
https://www.ncbi.nlm.nih.gov/pubmed/31341011
http://dx.doi.org/10.1042/BSR20190362

Ejemplares similares